Navigation Links
Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
Date:1/13/2009

MINNEAPOLIS, Jan. 13 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI) highlighted results from a clinical study of Macroplastique for the treatment of female stress urinary incontinence, now available in the January 2009 Journal of Urology. This is the first, large, multicenter randomized trial comparing the safety and efficacy of Macroplastique to another bulking agent used in the control group. In the Macroplastique group, the dry/cure rate was 36.9% versus 24.8% in the control group, with a 61.5% improvement compared to 48%, respectively. The authors conclude Macroplastique is a safe, effective, minimally invasive material that can be administered on an outpatient basis.

"This study shows the clear benefits of Macroplastique, an injectable soft tissue urethral bulking agent, bringing the majority of treated patients either freedom from unwanted urinary leakage or fewer episodes," said Uroplasty Chief Executive Officer and President David Kaysen. "Some other commercially available bulking agents may be absorbed into the body, potentially diminishing their clinical benefit. Macroplastique implants are suspended in a water-soluble gel that, once removed from the body, leaves behind the soft, flexible permanent elastomer implants that can sustain the treatment's benefits and provide patients with an improved outcome."

Macroplastique has been available to treat this condition worldwide since 1991. The majority of women treated with Macroplastique report a cure or improvement in their symptoms, with many seeing that improvement as soon as they leave the doctor's office, hospital or clinic.

The study, titled "Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: Results of a multicenter, randomized, controlled, single-blind study," followed 122 Macroplastique patients and a control group of 125 that received a commercially available bioabsorbable urethral bulking agent for one year.

  • Of the 247 study patients in the study, the average age was approximately 61 years, 73% were post-menopausal, about one fourth had previous failed urinary incontinence surgery, and over 50% had hysterectomies.
  • In the Macroplastique group, the dry/cure rate was 36.9% compared to 24.8% in the control group.
  • After 12 months, 61.5% of Macroplastique patients had improved 1 Stamey grade (a measure of incontinence improvement) compared to 48% of control patients.
  • The Macroplastique group's one-hour pad weight decrease was 25.4 ml from baseline compared to 22.8 ml for the control group.
  • Mean improvement for Macroplastique patients, in Urinary Incontinence Quality of Life Scores (I-QOL), was 28.7 compared to 26.4 for control patients.

An abstract of the study is available at: http://www.jurology.com/article/S0022-5347(08)02452-X/abstract

"I am pleased to have collaborated with leading Urologists and Urogynecologists throughout North American in conducting this study of Macroplastique," said Gamal Ghoniem, MD, Head, section of Voiding Dysfunction, Female Urology and Reconstruction and Chairman of Medical Education at Cleveland Clinic Florida and the study's primary author. "After treatment with Macroplastique, we measured clinical improvement to a patient's condition using a number of widely accepted outcome measures including cure rates, pad weight tests, and quality of life questionnaires. As a result, this study provides strong scientific evidence of the effectiveness of Macroplastique for the treatment of stress urinary incontinence.

In addition to Dr. Ghoniem, the study credits eleven other participating investigative sites in North America.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder. We also offer Macroplastique(R) Implants, an injectable bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at http://uroplasty.com.

For complete information regarding Macroplastique indications, contraindications, warnings, precautions, instructions for use, storage, adverse reactions and disclaimer of warranties, please refer to the instructions for use brochure available at the Uroplasty website.

    For Further Information: Uroplasty, Inc.   EVC Group
    David Kaysen, President and CEO, or        Doug Sherk (Investors)
    Medi Jiwani, Vice President, CFO, and      415.896.6820
     Treasurer                                 Chris Gale (Media)
    952.426.6140                               646.201.5431


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial
2. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
3. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
4. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
5. Symposium Highlights Yale Study Indicating Role of AHCC(R) for Immune System Enhancement and as a Promising Cancer Preventative
6. September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging
7. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
8. August 2008 Mayo Clinic Womens HealthSource Highlights Avoiding Blood Pressure Increase at Menopause, Healthful Benefits of Dark Chocolate and Scheduling a Colorectal Exam
9. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
10. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
11. June 2008 Mayo Clinic Womens HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding ... identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to ... the need to turn on a light when taking medication during the night, allowing ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
Breaking Medicine News(10 mins):